Inferior Alveolar Nerve Injuries
Conditions
Brief summary
This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and Lidocaine 2%. The type of LA will be concealed to the operator, investigators and assessors. The patients will be monitored for any aigns of nerve parathesia for 3 months after the procedure.
Interventions
DRUG4% Articaine with 1:200,000 epinephrine
Inferior Alveolar Nerve Block with 4% articaine
Inferior Alveolar Nerve Block with 2% lidocaine
Sponsors
Cleveland Dental Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with age between 18-55 years old * Patients need IANB * healthy patient
Exclusion criteria
* medical conditions * allergies * medications * pregnancy and breastfeeding * inability to provide informed consent * specific dental or medical history.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Electromyograph | 3 months | Signs of loss of sensation in the involved side of the jaw will be recorded using a tool called Electromyograph machine to evaluate and record Nerve conduction velocity, the scale is as follow Normal (grade 0) to extremely damage of (grade 6) while a patient rate pain intensity on a Visual Analogue Scale (VAS). |
Countries
United States
Contacts
Primary ContactPablo R Velazquez, Resident
Backup ContactNelson A Rendon, Resident
Outcome results
None listed